Literature DB >> 27435373

Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.

Heleen M van der Klift1,2, Arjen R Mensenkamp3, Mark Drost4, Elsa C Bik5, Yvonne J Vos6, Hans J J P Gille7, Bert E J W Redeker8, Yvonne Tiersma4, José B M Zonneveld5, Encarna Gómez García9, Tom G W Letteboer10, Maran J W Olderode-Berends6, Liselotte P van Hest7, Theo A van Os8, Senno Verhoef11,12, Anja Wagner13, Christi J van Asperen5, Sanne W Ten Broeke5, Frederik J Hes5, Niels de Wind4, Maartje Nielsen5, Peter Devilee4, Marjolijn J L Ligtenberg3,14, Juul T Wijnen5,4, Carli M J Tops5.   

Abstract

Monoallelic PMS2 germline mutations cause 5%-15% of Lynch syndrome, a midlife cancer predisposition, whereas biallelic PMS2 mutations cause approximately 60% of constitutional mismatch repair deficiency (CMMRD), a rare childhood cancer syndrome. Recently improved DNA- and RNA-based strategies are applied to overcome problematic PMS2 mutation analysis due to the presence of pseudogenes and frequent gene conversion events. Here, we determined PMS2 mutation detection yield and mutation spectrum in a nationwide cohort of 396 probands. Furthermore, we studied concordance between tumor IHC/MSI (immunohistochemistry/microsatellite instability) profile and mutation carrier state. Overall, we found 52 different pathogenic PMS2 variants explaining 121 Lynch syndrome and nine CMMRD patients. In vitro mismatch repair assays suggested pathogenicity for three missense variants. Ninety-one PMS2 mutation carriers (70%) showed isolated loss of PMS2 in their tumors, for 31 (24%) no or inconclusive IHC was available, and eight carriers (6%) showed discordant IHC (presence of PMS2 or loss of both MLH1 and PMS2). Ten cases with isolated PMS2 loss (10%; 10/97) harbored MLH1 mutations. We confirmed that recently improved mutation analysis provides a high yield of PMS2 mutations in patients with isolated loss of PMS2 expression. Application of universal tumor prescreening methods will however miss some PMS2 germline mutation carriers.
© 2016 WILEY PERIODICALS, INC.

Entities:  

Keywords:  CMMRD; Lynch syndrome; MLH1; PMS2; immunohistochemistry; mismatch repair; missense variants; pseudogenes

Mesh:

Substances:

Year:  2016        PMID: 27435373     DOI: 10.1002/humu.23052

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  20 in total

1.  Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Authors:  Daniel S Herman; Christina Smith; Chang Liu; Cecily P Vaughn; Selvi Palaniappan; Colin C Pritchard; Brian H Shirts
Journal:  J Mol Diagn       Date:  2018-05-22       Impact factor: 5.568

Review 2.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

3.  Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria.

Authors:  Maribel González-Acosta; Jesús Del Valle; Matilde Navarro; Bryony A Thompson; Sílvia Iglesias; Xavier Sanjuan; María José Paúles; Natàlia Padilla; Anna Fernández; Raquel Cuesta; Àlex Teulé; Guido Plotz; Juan Cadiñanos; Xavier de la Cruz; Francesc Balaguer; Conxi Lázaro; Marta Pineda; Gabriel Capellá
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

4.  A Lynch syndrome-associated mutation at a Bergerat ATP-binding fold destabilizes the structure of the DNA mismatch repair endonuclease MutL.

Authors:  Keisuke Izuhara; Kenji Fukui; Takeshi Murakawa; Seiki Baba; Takashi Kumasaka; Kazuhisa Uchiyama; Takato Yano
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

5.  The Perils of Single-Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next-Generation Sequencing.

Authors:  Nicole Casasanta; Elizabeth Stark; Allison McHenry; Tara Biagi; Rebecca Kaltman
Journal:  Oncologist       Date:  2018-02-14

6.  Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing.

Authors:  Barbara Luísa Soares; Ayslan Castro Brant; Renan Gomes; Tatiane Pastor; Naye Balzan Schneider; Ândrea Ribeiro-Dos-Santos; Paulo Pimentel de Assumpção; Maria Isabel W Achatz; Patrícia Ashton-Prolla; Miguel Angelo Martins Moreira
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

7.  An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.

Authors:  Marion Jaffrelot; Nadim Farés; Rosine Guimbaud; Janick Selves; Anne Cécile Brunac; Anne Pascale Laurenty; Marie Danjoux; David Grand; Samira Icher; Julie Meilleroux; Eliane Mery; Etienne Buscail; Charlotte Maulat; Christine Toulas; Pierre Vande Perre; Edith Chipoulet; Delphine Bonnet; Anne Staub
Journal:  Mod Pathol       Date:  2021-09-20       Impact factor: 7.842

8.  In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation.

Authors:  Ester Borras; Kyle Chang; Mala Pande; Amanda Cuddy; Jennifer L Bosch; Sarah A Bannon; Maureen E Mork; Miguel A Rodriguez-Bigas; Melissa W Taggart; Patrick M Lynch; Y Nancy You; Eduardo Vilar
Journal:  Cancer Prev Res (Phila)       Date:  2017-08-01

9.  The impact of hereditary cancer gene panels on clinical care and lessons learned.

Authors:  Volkan Okur; Wendy K Chung
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-11-21

10.  Single nucleotide polymorphisms in MLH1 predict poor prognosis of hepatocellular carcinoma in a Chinese population.

Authors:  Xiaonian Zhu; Wei Liu; Xiaoqiang Qiu; Zhigang Wang; Chao Tan; Chunhua Bei; Linyuan Qin; Yuan Ren; Shengkui Tan
Journal:  Oncotarget       Date:  2017-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.